IAMA Therapeutics is a clinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and started the Phase 1 clinical trial in January 2024. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Genova, It
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://iamatherapeutics.com/
- Keywords
- Foresee Biosystems.
- HQ
- Genova
Iama Therapeutics Questions
Iama Therapeutics's website is https://iamatherapeutics.com/
Iama Therapeutics's LinkedIn profile is https://it.linkedin.com/company/iamatherapeutics
Iama Therapeutics has
8 employees.
View email and phone details for 8
employees at Iama Therapeutics.
Iama Therapeutics's industry is
Pharmaceutical Manufacturing
Iama Therapeutics's top competitors are
Istituto Italiano Di Tecnologia,
Alia Therapeutics,
Sibylla Biotech,
Foresee Biosystems,
Corticale Srl,
Genenta Science (Nasdaq: Gnta),
Kither Biotech,
Altheia Science,
Resalis Therapeutics,
Prebiomics.
Iama Therapeutics's categories are Pharmaceutical Manufacturing
Iama Therapeutics's founding year is 2021
